Companies

All
Industries

Biotechnology

Human Genome Sciences Inc. / See Company Profile

Acquisition / Glaxo makes unsolicited offer to buy HGS for $2.6bn / Strategic Transactions / Deal Date: Apr. 1, 2012 / Update Date: May 1, 2012

Alliance / HGS pays $50mm up front for rights to FivePrime anticancer candidate / Strategic Transactions / Deal Date: Mar. 1, 2011 / Publish Date: Mar. 22, 2011

Alliance / GSK exercises option to HGS's LymphoStat-B / Strategic Transactions / Deal Date: Jul. 1, 2005 / Update Date: Mar. 1, 2011

Dynavax Technologies Corp. / See Company Profile

Financing / Dynavax nets $69.9mm via FOPO / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 1, 2012

Alliance / Dynavax and AstraZeneca develop respiratory treatments / Strategic Transactions / Deal Date: Sep. 1, 2006 / Update Date: Dec. 1, 2011

Alliance / GSK options Dynavax's TLR inhibitors / Strategic Transactions / Deal Date: Dec. 1, 2008 / Update Date: Dec. 1, 2011

Action Pharma AS / See Company Profile

Alliance / Abbott acquires Action Pharma's Phase II renal compound AP214 / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 4, 2012

Alliance / Action Pharma licenses Zealand Pharma’s kidney drug candidate and technology; later transfers rights to Abbott / Strategic Transactions / Deal Date: Apr. 1, 2003 / Update Date: May 1, 2012

Financing / Action Pharma brings in €5mm through its Series D round / Strategic Transactions / Deal Date: Jun. 1, 2010 / Publish Date: Jul. 28, 2010

---

Medical Devices

Kensey Nash Corp. / See Company Profile

Acquisition / Royal DSM pays $38.50 per share in cash for Kensey Nash / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 5, 2012

Acquisition / Spectranetics buys Kensey Nash's endovascular unit / Strategic Transactions / Deal Date: May 1, 2008 / Update Date: Dec. 1, 2011

Acquisition / Kensey Nash buys Synthes' Norian for $22mm in cash / Strategic Transactions / Deal Date: May 1, 2011 / Publish Date: May 28, 2011

Guangzhou Bioseal Biotechnology Co. Ltd. / See Company Profile

Acquisition / Johnson & Johnson buys Guangzhou Bioseal Biotechnology / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 4, 2012

---

In Vitro Diagnostics

Islet Sciences Inc. / See Company Profile

Alliance / Islet Sciences licenses technology from Yale for use in developing diabetes diagnostic / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 9, 2012

Acquisition / Islet Sciences issues shares to acquire diabetes drug developer DiaKine / Strategic Transactions / Deal Date: Feb. 1, 2012 / Publish Date: Mar. 9, 2012

Financing / DiaKine Therapeutics raises additional funds / Strategic Transactions / Deal Date: Sep. 1, 2008 / Publish Date: Nov. 1, 2008

Oxford Nanopore Technologies Ltd. / See Company Profile

Financing / Oxford Nanopore completes £31.4mm Series G round / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 11, 2012

Alliance / Illumina takes $18mm stake in Oxford Nanopore and rights to BASE / Strategic Transactions / Deal Date: Jan. 1, 2009 / Publish Date: May 13, 2011

Financing / Oxford Nanopore raises £2.1mm in Series D financing / Strategic Transactions / Deal Date: Jan. 1, 2009 / Publish Date: May 10, 2011

---

Pharmaceuticals

GlaxoSmithKline PLC / See Company Profile

Alliance / Dainippon to co-promote GSK’s Paxil CR in Japan / Strategic Transactions / Deal Date: Mar. 1, 2012 / Publish Date: May 5, 2012

Alliance / GSK, Yale to discover proteolysis-targeting chimeric molecules / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 5, 2012

Acquisition / Glaxo makes unsolicited offer to buy HGS for $2.6bn / Strategic Transactions / Deal Date: Apr. 1, 2012 / Update Date: May 1, 2012

Johnson & Johnson / See Company Profile

Acquisition / Johnson & Johnson buys Guangzhou Bioseal Biotechnology / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 4, 2012

Alliance / Recordati gets German rights to six OTC products from J&J's Cilag, McNeil / Strategic Transactions / Deal Date: Apr. 1, 2012 / Publish Date: Apr. 28, 2012

Alliance / Ethicon acquires Quill IP from Angiotech Pharmaceuticals for up to $62mm / Strategic Transactions / Deal Date: Apr. 1, 2012 / Publish Date: Apr. 13, 2012

Abbott Laboratories Inc. / See Company Profile

Alliance / Abbott acquires Action Pharma's Phase II renal compound AP214 / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 4, 2012

Alliance / Stanford University licenses Abbott Molecular rights to prostate cancer biomarkers / Strategic Transactions / Deal Date: Apr. 1, 2012 / Publish Date: Apr. 21, 2012

Alliance / Galapagos licenses Phase II RA candidate to Abbott / Strategic Transactions / Deal Date: Feb. 1, 2012 / Publish Date: Mar. 1, 2012

Biotechnology

Biotechnology

Human Genome Sciences Inc. / See Company Profile

Acquisition / Glaxo makes unsolicited offer to buy HGS for $2.6bn / Strategic Transactions / Deal Date: Apr. 1, 2012 / Update Date: May 1, 2012

Alliance / HGS pays $50mm up front for rights to FivePrime anticancer candidate / Strategic Transactions / Deal Date: Mar. 1, 2011 / Publish Date: Mar. 22, 2011

Alliance / GSK exercises option to HGS's LymphoStat-B / Strategic Transactions / Deal Date: Jul. 1, 2005 / Update Date: Mar. 1, 2011

Dynavax Technologies Corp. / See Company Profile

Financing / Dynavax nets $69.9mm via FOPO / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 1, 2012

Alliance / Dynavax and AstraZeneca develop respiratory treatments / Strategic Transactions / Deal Date: Sep. 1, 2006 / Update Date: Dec. 1, 2011

Alliance / GSK options Dynavax's TLR inhibitors / Strategic Transactions / Deal Date: Dec. 1, 2008 / Update Date: Dec. 1, 2011

Action Pharma AS / See Company Profile

Alliance / Abbott acquires Action Pharma's Phase II renal compound AP214 / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 4, 2012

Alliance / Action Pharma licenses Zealand Pharma’s kidney drug candidate and technology; later transfers rights to Abbott / Strategic Transactions / Deal Date: Apr. 1, 2003 / Update Date: May 1, 2012

Financing / Action Pharma brings in €5mm through its Series D round / Strategic Transactions / Deal Date: Jun. 1, 2010 / Publish Date: Jul. 28, 2010

Medical
Devices

Medical Devices

Kensey Nash Corp. / See Company Profile

Acquisition / Royal DSM pays $38.50 per share in cash for Kensey Nash / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 5, 2012

Acquisition / Spectranetics buys Kensey Nash's endovascular unit / Strategic Transactions / Deal Date: May 1, 2008 / Update Date: Dec. 1, 2011

Acquisition / Kensey Nash buys Synthes' Norian for $22mm in cash / Strategic Transactions / Deal Date: May 1, 2011 / Publish Date: May 28, 2011

Guangzhou Bioseal Biotechnology Co. Ltd. / See Company Profile

Acquisition / Johnson & Johnson buys Guangzhou Bioseal Biotechnology / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 4, 2012

In Vitro
Diagnostics

In Vitro Diagnostics

Islet Sciences Inc. / See Company Profile

Alliance / Islet Sciences licenses technology from Yale for use in developing diabetes diagnostic / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 9, 2012

Acquisition / Islet Sciences issues shares to acquire diabetes drug developer DiaKine / Strategic Transactions / Deal Date: Feb. 1, 2012 / Publish Date: Mar. 9, 2012

Financing / DiaKine Therapeutics raises additional funds / Strategic Transactions / Deal Date: Sep. 1, 2008 / Publish Date: Nov. 1, 2008

Oxford Nanopore Technologies Ltd. / See Company Profile

Financing / Oxford Nanopore completes £31.4mm Series G round / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 11, 2012

Alliance / Illumina takes $18mm stake in Oxford Nanopore and rights to BASE / Strategic Transactions / Deal Date: Jan. 1, 2009 / Publish Date: May 13, 2011

Financing / Oxford Nanopore raises £2.1mm in Series D financing / Strategic Transactions / Deal Date: Jan. 1, 2009 / Publish Date: May 10, 2011

Pharmaceuticals

Pharmaceuticals

GlaxoSmithKline PLC / See Company Profile

Alliance / Dainippon to co-promote GSK’s Paxil CR in Japan / Strategic Transactions / Deal Date: Mar. 1, 2012 / Publish Date: May 5, 2012

Alliance / GSK, Yale to discover proteolysis-targeting chimeric molecules / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 5, 2012

Acquisition / Glaxo makes unsolicited offer to buy HGS for $2.6bn / Strategic Transactions / Deal Date: Apr. 1, 2012 / Update Date: May 1, 2012

Johnson & Johnson / See Company Profile

Acquisition / Johnson & Johnson buys Guangzhou Bioseal Biotechnology / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 4, 2012

Alliance / Recordati gets German rights to six OTC products from J&J's Cilag, McNeil / Strategic Transactions / Deal Date: Apr. 1, 2012 / Publish Date: Apr. 28, 2012

Alliance / Ethicon acquires Quill IP from Angiotech Pharmaceuticals for up to $62mm / Strategic Transactions / Deal Date: Apr. 1, 2012 / Publish Date: Apr. 13, 2012

Abbott Laboratories Inc. / See Company Profile

Alliance / Abbott acquires Action Pharma's Phase II renal compound AP214 / Strategic Transactions / Deal Date: May 1, 2012 / Publish Date: May 4, 2012

Alliance / Stanford University licenses Abbott Molecular rights to prostate cancer biomarkers / Strategic Transactions / Deal Date: Apr. 1, 2012 / Publish Date: Apr. 21, 2012

Alliance / Galapagos licenses Phase II RA candidate to Abbott / Strategic Transactions / Deal Date: Feb. 1, 2012 / Publish Date: Mar. 1, 2012